Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.
Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S. Darb-Esfahani S, et al. Among authors: ataseven b. Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18. Br J Cancer. 2012. PMID: 23079573 Free PMC article.
Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients.
Marchetti C, Ataseven B, Cassani C, Sassu CM, Congedo L, D'Indinosante M, Cappuccio S, Rhiem K, Hahnen E, Lucci Cordisco E, Arbustini E, Harter P, Minucci A, Scambia G, Fagotti A. Marchetti C, et al. Among authors: ataseven b. Int J Gynecol Cancer. 2023 Feb 6;33(2):257-262. doi: 10.1136/ijgc-2022-003893. Int J Gynecol Cancer. 2023. PMID: 36581488
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Steenbeek MP, van Bommel MHD, intHout J, Peterson CB, Simons M, Roes KCB, Kets M, Norquist BM, Swisher EM, Hermens RPMG; TUBA-WISP II consortium; Lu KH, de Hullu JA. Steenbeek MP, et al. Int J Gynecol Cancer. 2023 Jun 5;33(6):982-987. doi: 10.1136/ijgc-2023-004377. Int J Gynecol Cancer. 2023. PMID: 37045546 Free PMC article.
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Mirza MR, et al. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972026 Clinical Trial.
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
Marchetti C, Ataseven B, Perrone AM, Cassani C, Fruscio R, Sassu CM, Apostol AI, Harter P, De Iaco P, Camnasio CA, Moubarak M, Giannarelli D, Scambia G, Fagotti A. Marchetti C, et al. Among authors: ataseven b. Gynecol Oncol. 2024 Aug;187:170-177. doi: 10.1016/j.ygyno.2024.05.008. Epub 2024 May 23. Gynecol Oncol. 2024. PMID: 38788514
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H, Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M; German Adjuvant Breast Cancer Group. Eiermann W, et al. Among authors: ataseven b. Eur J Cancer. 2010 Jan;46(1):84-94. doi: 10.1016/j.ejca.2009.10.001. Eur J Cancer. 2010. PMID: 19879750 Clinical Trial.
Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer JU, Ataseven B, Weiss E, Tesch H, Gerber B, Baumann KH, Thomssen C, Breitbach GP, Ibishi S, Jackisch C, Mehta K, von Minckwitz G. Costa SD, et al. Among authors: ataseven b. J Clin Oncol. 2010 Jan 1;28(1):83-91. doi: 10.1200/JCO.2009.23.5101. Epub 2009 Nov 9. J Clin Oncol. 2010. PMID: 19901111 Clinical Trial.
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C. Loibl S, et al. Among authors: ataseven b. Breast Cancer Res Treat. 2011 Nov;130(2):477-87. doi: 10.1007/s10549-011-1715-8. Epub 2011 Aug 12. Breast Cancer Res Treat. 2011. PMID: 21837479
BRCA2 mutations and triple-negative breast cancer.
Meyer P, Landgraf K, Högel B, Eiermann W, Ataseven B. Meyer P, et al. Among authors: ataseven b. PLoS One. 2012;7(5):e38361. doi: 10.1371/journal.pone.0038361. Epub 2012 May 30. PLoS One. 2012. PMID: 22666503 Free PMC article.
119 results